Suchergebnisse - "Karabajakian, Andy"

PubPharm (22)

1

Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes

enthalten in: Oral oncology | 2024

von Le Meitour, Y. | Foy, J. | Guinand, M. | +5

2

Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer

enthalten in: The New England journal of medicine | 2023

von Hadoux, J. | Elisei, R. | Brose, M. | +122

3

Uterin adenosarcoma : French Guidelines of the French Sarcoma Group and the Rare Gynecologic Tumor Group

enthalten in: Bulletin du cancer | 2023

von Karabajakian, A. | Genestie, C. | Meeus, P. | +8

4

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

enthalten in: bioRxiv.org | 2023

von Prasad, M. | Zorea, J. | Jagadeeshan, S. | +26

5

Addendum : Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

enthalten in: Oncotarget | 2022

von Karabajakian, A. | Garrivier, T. | Crozes, C. | +8

6

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Foy, J. | Karabajakian, A. | Ortiz-Cuaran, S. | +22

7

Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors

enthalten in: Data in brief | 2022

von Foy, J. | Karabajakian, A. | Ortiz-Cuaran, S. | +22

8

Molecular Mechanisms of Kaposi Sarcoma Development

enthalten in: Cancers | 2022

von Karabajakian, A. | Ray-Coquard, I. | Blay, J.

9

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

enthalten in: Journal for immunotherapy of cancer | 2022

von Prasad, M. | Zorea, J. | Jagadeeshan, S. | +29

10

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

enthalten in: Journal for ImmunoTherapy of Cancer | March 15, 2022

von Prasad, M. | Zorea, J. | Jagadeeshan, S. | +29